Compare CSIQ & SDGR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | CSIQ | SDGR |
|---|---|---|
| Founded | 2001 | 1990 |
| Country | Canada | United States |
| Employees | 17113 | N/A |
| Industry | Semiconductors | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 824.4M | 850.5M |
| IPO Year | 2006 | 2020 |
| Metric | CSIQ | SDGR |
|---|---|---|
| Price | $12.64 | $11.29 |
| Analyst Decision | Hold | Buy |
| Analyst Count | 10 | 8 |
| Target Price | $17.36 | ★ $21.13 |
| AVG Volume (30 Days) | ★ 2.5M | 939.5K |
| Earning Date | 05-14-2026 | 05-06-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 45.14 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $255,869,000.00 |
| Revenue This Year | $23.95 | $1.20 |
| Revenue Next Year | $13.58 | $4.36 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 23.29 |
| 52 Week Low | $6.85 | $10.95 |
| 52 Week High | $34.59 | $27.63 |
| Indicator | CSIQ | SDGR |
|---|---|---|
| Relative Strength Index (RSI) | 36.72 | 39.46 |
| Support Level | $11.00 | $11.03 |
| Resistance Level | $13.73 | $13.36 |
| Average True Range (ATR) | 0.83 | 0.48 |
| MACD | 0.02 | 0.05 |
| Stochastic Oscillator | 29.35 | 28.85 |
Canadian Solar Inc is a Canadian solar technology and renewable energy company. It is a manufacturer of solar photovoltaic modules, a provider of battery energy storage solutions, and a developer of utility-scale solar power and battery energy storage projects.. It operates through two business segments CSI Solar and Recurrent Energy segment. The CSI Solar segment focused on solar modules and battery energy storage manufacturing and products. Its Recurrent segment focused on utility-scale solar power and battery energy storage project development and operation. Key revenue is generated from CSI Solar segment.
Schrodinger Inc is a healthcare-based software company. It offers software solutions designed to support and accelerate the discovery, design, and optimization of molecules. The company operates in two reportable segments: Software and Drug Discovery. The software segment is focused on selling software to transform drug discovery across the life sciences industry, as well as to customers in materials science industries. The drug discovery segment is focused on generating revenue from a diverse portfolio of preclinical and clinical programs, internally and through collaborations, that have various stages of discovery and development. The majority of the company's revenue is derived from the Software segment. Geographically, it derives the maximum revenue from the United States.